株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

肝疾患治療市場(化学療法、抗ウイルス薬、ワクチン、標的療法と免疫抑制) - 世界の産業分析、サイズ、シェア、動向と予測

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

発行 Transparency Market Research 商品コード 259902
出版日 ページ情報 英文 112 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
肝疾患治療市場(化学療法、抗ウイルス薬、ワクチン、標的療法と免疫抑制) - 世界の産業分析、サイズ、シェア、動向と予測 Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
出版日: 2013年01月16日 ページ情報: 英文 112 Pages
概要

当レポートは、肝疾患治療薬の世界市場を、抗ウイルス薬、ワクチン、免疫抑制剤、免疫グロブリン、標的療法、コルチコステロイド、化学療法の7薬剤に分類し、市場規模の推計および予測と、年間成長率を提供しています。さらにAbbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, PfizerとRocheの各主要な市場プレーヤを考慮に入れて市場に対する深い競合分析を行い、ビジネス戦略の詳細な分析、企業の概要、財務の概要、製品ポートフォリオと最近の動向も提供しており、肝臓疾患治療薬市場の売上の詳細な分析とセグメントごとの傾向分析を交え、概略下記内容でお届け致します。

第1章 はじめに

  • 本レポートの説明
  • 調査方法

第2章 エグゼクティブサマリー

第3章 市場の概要

  • はじめに
  • 市場規模
  • 薬剤クラス別世界の肝疾患治療薬市場の比較分析
  • 肝疾患治療薬の市場力学
    • 成長促進要因
    • 肝疾患治療薬市場促進要因の影響分析
    • 制約要因
    • 肝疾患治療薬市場の制約要因の影響分析
    • 機会
  • 肝疾患治療薬市場に対するポーターのファイブフォース分析
    • サプライヤの交渉力
    • バイヤーの交渉力
    • 新規参入の脅威
    • 代替品の脅威
    • 競合者による競争

第4章肝疾患の分類と治療の選択肢

  • アルコール性肝疾患
  • 自己免疫肝障害
  • 肝細胞癌
  • 非アルコール性脂肪肝疾患
  • ウイルス性/肝炎肝障害
    • 肝炎
    • B型肝炎
    • C型肝炎
    • D型肝炎
    • E型肝炎

第5章 薬剤クラス別肝疾患治療薬市場

  • 肝疾患の治療のための免疫抑制剤世界市場
  • 肝疾患の治療のための化学療法薬世界市場
  • 肝疾患の治療のための標的治療薬世界市場
  • 肝疾患の治療のためのワクチン世界市場
  • 肝疾患の治療のための抗ウイルス薬世界市場
  • 肝疾患の治療のための免疫グロブリン世界市場
  • 肝疾患の治療のためのコルチコステロイド世界市場

第6章 競合展望

  • 薬剤クラス別肝疾患治療薬市場の主要企業の市場シェア
    • 肝疾患の免疫抑制剤市場における主要企業の市場シェア
    • 肝疾患用ワクチン市場における主要企業の市場シェア
    • 肝疾患の抗ウイルス薬市場における主要企業の市場シェア
    • 肝疾患の標的療法における主要企業の市場シェア
    • 新規参入(フェーズ?)
    • キープレーヤー別の競争戦略
    • 新規参入者の競争戦略
    • 協定と協業

第7章提言

  • 成功のための市場戦略
  • 考慮すべき制約

第8章 企業プロフィール

目次

Abstract

Description

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate.

This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our analysis with C-level executives of major companies operating in liver diseases therapeutics market through the means of primary research to finally come up with our results. This research is specially designed to estimate and analyze the performance of liver diseases therapeutics in a global scenario. This research provides in-depth analysis of liver diseases therapeutics market sales, trend analysis by segments.

Table of Contents

CHAPTER 1 PREFACE

  • 1.1 REPORT DESCRIPTION
  • 1.2 RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW

  • 3.1 INTRODUCTION
  • 3.2 MARKET SIZE
  • 3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
  • 3.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
    • 3.4.1 DRIVERS
      • 3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis and liver cancer
      • 3.4.1.2 Increasing global prevalence of liver diseases
      • 3.4.1.3 High unmet needs exist in the liver cancer therapeutics
      • 3.4.1.4 Increased vaccination in emerging economies
    • 3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS
    • 3.4.3 RESTRAINTS
      • 3.4.3.1 Side-effects and risks
      • 3.4.3.2 FDA approvals and other government regulations
      • 3.4.3.3 Availability of alternate treatment procedures
    • 3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS
    • 3.4.5 OPPORTUNITIES
      • 3.4.5.1 Strong pipeline drugs
      • 3.4.5.2 Emerging economies in Asia, Latin America and Eastern European countries
      • 3.4.5.3 Consolidation opportunities in the healthcare industry
  • 3.5 PORTER'S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET
    • 3.5.1 BARGAINING POWER OF SUPPLIERS
    • 3.5.2 BARGAINING POWER OF BUYERS
    • 3.5.3 THREAT OF NEW ENTRANTS
    • 3.5.4 THREAT OF SUBSTITUTES
    • 3.5.5 COMPETITIVE RIVALRY

CHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS

  • 4.1 ALCOHOL INDUCED LIVER DISEASE
    • 4.1.1 OVERVIEW
    • 4.1.2 EPIDEMIOLOGY
    • 4.1.3 ETIOLOGY
    • 4.1.4 SYMPTOMS
    • 4.1.5 PATHOPHYSIOLOGY
    • 4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
      • 4.1.6.1 Anabolic Steroids
      • 4.1.6.2 Alcohol Abuse Drugs
  • 4.2 AUTOIMMUNE LIVER DISORDER
    • 4.2.1 AUTOIMMUNE HEPATITIS (AIH)
      • 4.2.1.1 OVERVIEW
      • 4.2.1.2 EPIDEMIOLOGY
      • 4.2.1.3 ETIOLOGY
      • 4.2.1.4 SYMPTOMS
      • 4.2.1.5 PATHOPHYSIOLOGY
      • 4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
        • 4.2.1.6.1 Antimetabolites
        • 4.2.1.6.2 Corticosteroids
  • 4.3 HEPATOCELLULAR CARCINOMA
    • 4.3.1 OVERVIEW
    • 4.3.2 EPIDEMIOLOGY
    • 4.3.3 ETIOLOGY
    • 4.3.4 SYMPTOMS
    • 4.3.5 PATHOPHYSIOLOGY
    • 4.3.6 TREATMENT PATTERN AND THERAPY OPTIONS
      • 4.3.6.1 Chemotherapy
      • 4.3.6.2 Targeted Therapy
  • 4.4 NON-ALCOHOLIC FATTY LIVER DISEASE
    • 4.4.1 OVERVIEW
    • 4.4.2 EPIDEMIOLOGY
    • 4.4.3 ETIOLOGY
    • 4.4.4 SYMPTOMS
    • 4.4.5 PATHOPHYSIOLOGY
    • 4.4.6 TREATMENT PATTERN AND THERAPY OPTIONS
      • 4.4.6.1 Gallstone solubilising drugs
  • 4.5 VIRAL/HEPATITIS LIVER DISORDER
    • 4.5.1 HEPATITIS A
      • 4.5.1.1 OVERVIEW
      • 4.5.1.2 EPIDEMIOLOGY
      • 4.5.1.3 ETIOLOGY
      • 4.5.1.4 SYMPTOMS
      • 4.5.1.5 PATHOPHYSIOLOGY
      • 4.5.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
        • 4.5.1.6.1 Vaccines
        • 4.5.1.6.2 Immunoglobulins
    • 4.5.2 HEPATITIS B
      • 4.5.2.1 OVERVIEW
      • 4.5.2.2 EPIDEMIOLOGY
      • 4.5.2.3 ETIOLOGY
      • 4.5.2.4 SYMPTOMS
      • 4.5.2.5 PATHOPHYSIOLOGY
      • 4.5.2.6 TREATMENT PATTERN AND THERAPY OPTIONS
        • 4.5.2.6.1 Antiviral drugs
        • 4.5.2.6.2 Immunoglobulins
        • 4.5.2.6.3 Vaccines
    • 4.5.3 HEPATITIS C
      • 4.5.3.1 OVERVIEW
      • 4.5.3.2 EPIDEMIOLOGY
      • 4.5.3.3 ETIOLOGY
      • 4.5.3.4 SYMPTOMS
      • 4.5.3.5 PATHOPHYSIOLOGY
      • 4.5.3.6 TREATMENT PATTERN AND THERAPY OPTIONS
        • 4.5.3.6.1 Antiviral drugs
    • 4.5.4 HEPATITIS D
      • 4.5.4.1 OVERVIEW
      • 4.5.4.2 EPIDEMIOLOGY
      • 4.5.4.3 ETIOLOGY
      • 4.5.4.4 SYMPTOMS
      • 4.5.4.5 PATHOPHYSIOLOGY
      • 4.5.4.6 TREATMENT PATTERN AND THERAPY OPTIONS
    • 4.5.5 HEPATITIS E
      • 4.5.5.1 OVERVIEW
      • 4.5.5.2 EPIDEMIOLOGY
      • 4.5.5.3 ETIOLOGY
      • 4.5.5.4 SYMPTOMS
      • 4.5.5.5 PATHOPHYSIOLOGY
      • 4.5.5.6 TREATMENT PATTERN AND THERAPY OPTIONS

CHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS

  • 5.1 IMMUNOSUPPRESSANTS
    • 5.1.1 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • 5.2 CHEMOTHERAPY DRUGS
    • 5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • 5.3 TARGETED THERAPY DRUGS
    • 5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • 5.4 VACCINES
    • 5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • 5.5 ANTI-VIRAL DRUGS
    • 5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • 5.6 IMMUNOGLOBULINS
    • 5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • 5.7 CORTICOSTERIODS
    • 5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)

CHAPTER 6 COMPETITIVE LANDSCAPE

  • 6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUG CLASS
    • 6.1.1 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES
    • 6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES
    • 6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES
    • 6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES
    • 6.1.5 NEW ENTRANTS (PHASE III)
    • 6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS
      • 6.1.6.1 Investments in R&D and clinical studies
      • 6.1.6.2 Entering the emerging economies
      • 6.1.6.3 Investing in different segments of the market
    • 6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS
    • 6.1.8 AGREEMENTS AND COLLABORATIONS

CHAPTER 7 RECOMMENDATIONS

  • 7.1 MARKET STRATEGY FOR SUCCESS
  • 7.2 BARRIERS TO BE CONSIDERED

CHAPTER 8 COMPANY PROFILES

  • 8.1 ABBOTT LABORATORIES
    • 8.1.1 COMPANY OVERVIEW
    • 8.1.2 FINANCIAL OVERVIEW
    • 8.1.3 BUSINESS STRATEGIES
      • 8.1.3.1 Significant R&D investments for new products development
      • 8.1.3.2 Investing in emerging markets
      • 8.1.3.3 Conducting clinical trials
    • 8.1.4 PRODUCT PORTFOLIO
    • 8.1.5 RECENT DEVELOPMENTS
  • 8.2 ASTELLAS PHARMA INC.
    • 8.2.1 COMPANY OVERVIEW
    • 8.2.2 FINANCIAL OVERVIEW
    • 8.2.3 BUSINESS STRATEGIES
      • 8.2.3.1 Investing in emerging economies
      • 8.2.3.2 Investing in research and development
    • 8.2.4 PRODUCT PORTFOLIO
    • 8.2.5 RECENT DEVELOPMENTS
  • 8.3 BRISTOL-MYERS SQUIBB
    • 8.3.1 COMPANY OVERVIEW
    • 8.3.2 FINANCIAL OVERVIEW
    • 8.3.3 BUSINESS STRATEGIES
      • 8.3.3.1 Mergers, acquisitiosn and strategic development
      • 8.3.3.2 Investing in research and development
    • 8.3.4 PRODUCT PORTFOLIO
    • 8.3.5 RECENT DEVELOPMENTS
  • 8.4 GILEAD SCIENCES
    • 8.4.1 COMPANY OVERVIEW
    • 8.4.2 FINANCIAL OVERVIEW
    • 8.4.3 BUSINESS STRATEGIES
      • 8.4.3.1 Innovative new products
      • 8.4.3.2 Investing in research and development
    • 8.4.4 PRODUCT PORTFOLIO
    • 8.4.5 RECENT DEVELOPMENTS
  • 8.5 GLAXOSMITHKLINE PLC
    • 8.5.1 COMPANY OVERVIEW
    • 8.5.2 FINANCIAL OVERVIEW
    • 8.5.3 BUSINESS STRATEGIES
      • 8.5.3.1 Research and development investments
      • 8.5.3.2 Delivering new products
    • 8.5.4 PRODUCT PORTFOLIO
    • 8.5.5 RECENT DEVELOPMENTS
  • 8.6 F. HOFFMANN-LA ROCHE LTD
    • 8.6.1 COMPANY OVERVIEW
    • 8.6.2 FINANCIAL OVERVIEW
    • 8.6.3 BUSINESS STRATEGIES
      • 8.6.3.1 Strategic alliance initiative
      • 8.6.3.2 Investing in research and development
    • 8.6.4 PRODUCT PORTFOLIO
    • 8.6.5 RECENT DEVELOPMENTS
  • 8.7 MERCK & CO. INC
    • 8.7.1 COMPANY OVERVIEW
    • 8.7.2 FINANCIAL OVERVIEW
    • 8.7.3 BUSINESS STRATEGIES
      • 8.7.3.1 R&D initiatives
      • 8.7.3.2 Strategic alliance
      • 8.7.3.3 Corporate social responsibility and awareness
    • 8.7.4 PRODUCT PORTFOLIO
    • 8.7.5 RECENT DEVELOPMENTS
  • 8.8 NOVARTIS AG
    • 8.8.1 COMPANY OVERVIEW
    • 8.8.2 FINANCIAL OVERVIEW
    • 8.8.3 BUSINESS STRATEGIES
      • 8.8.3.1 Strategic alliance
      • 8.8.3.2 Investing in research and development
    • 8.8.4 PRODUCT PORTFOLIO
    • 8.8.5 RECENT DEVELOPMENTS
  • 8.9 SANOFI S.A
    • 8.9.1 COMPANY OVERVIEW
    • 8.9.2 FINANCIAL OVERVIEW
    • 8.9.3 BUSINESS STRATEGIES
      • 8.9.3.1 Business Diversification
      • 8.9.3.2 Research and development initiative
    • 8.9.4 PRODUCT PORTFOLIO
    • 8.9.5 RECENT DEVELOPMENTS
  • 8.10 PFIZER INC.
    • 8.10.1 COMPANY OVERVIEW
    • 8.10.2 FINANCIAL OVERVIEW
    • 8.10.3 BUSINESS STRATEGIES
      • 8.10.3.1 Investing in research and development
    • 8.10.4 PRODUCT PORTFOLIO
    • 8.10.5 RECENT DEVELOPMENTS
  • 8.11 TAKEDA PHARMACEUTICAL
    • 8.11.1 COMPANY OVERVIEW
    • 8.11.2 FINANCIAL OVERVIEW
    • 8.11.3 BUSINESS STRATEGIES
      • 8.11.3.1 Investing in emerging economies
      • 8.11.3.2 Investing in research and development
    • 8.11.4 PRODUCT PORTFOLIO
    • 8.11.5 RECENT DEVELOPMENTS
  • 8.12 VALEANT PHARMACEUTICALS
    • 8.12.1 COMPANY OVERVIEW
    • 8.12.2 FINANCIAL OVERVIEW
    • 8.12.3 BUSINESS STRATEGIES
      • 8.12.3.1 Strategic alliance
    • 8.12.4 PRODUCT PORTFOLIO
    • 8.12.5 RECENT DEVELOPMENTS
  • 8.13 WATSON PHARMACEUTICALS, INC.
    • 8.13.1 COMPANY OVERVIEW
    • 8.13.2 FINANCIAL OVERVIEW
    • 8.13.3 BUSINESS STRATEGIES
      • 8.13.3.1 Investing in generic and biosimilar segments
      • 8.13.3.2 Investing in research and development
    • 8.13.4 PRODUCT PORTFOLIO
    • 8.13.5 RECENT DEVELOPMENTS

LIST OF FIGURES

  • FIG. 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 (USD MILLION)
  • FIG. 2 LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION
  • FIG. 3 COMPARATIVE MARKET SHARE ANALYSIS OF GLOBAL LIVER DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
  • FIG. 4 PORTER'S FIVE FORCES ANALYSIS FOR THE LIVER DISEASES THERAPEUTICS MARKET
  • FIG. 5 PROGRESSION OF ALCOHOL INDUCED LIVER DISEASE IN HEAVY DRINKERS
  • FIG. 6 PROGRESSION OF HEPATOCELLULAR CANCER
  • FIG. 7 TWO-HIT CONCEPT OF NON-ALCOHOLIC FATTY LIVER DISEASE
  • FIG. 8 PATHOGENESIS OF HEPATITIS A VIRUS
  • FIG. 9 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • FIG. 10 GLOBAL CHEMOTHERAPY MARKET FOR LIVER DISEASE THERAPEUTICS , 2010 - 2018 (USD MILLION)
  • FIG. 11 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 2018 (USD MILLION)
  • FIG. 12 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • FIG. 13 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • FIG. 14 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 - 2018 (USD MILLION)
  • FIG. 15 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES, 2011 (%)
  • FIG. 16 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES, 2011 (%)
  • FIG. 17 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES, 2011 (%)
  • FIG. 18 ABBOTT LABORATORIES NET SALES, 2008-2011 (USD MILLION)
  • FIG. 19 ASTELLAS PHARMA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 20 BRISTOL-MYERS SQUIBB ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 21 GILEAD SCIENCE ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 22 GLAXO SMITHKLINE ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 23 F. HOFFMANN-LA ROCHE LTD. ANNUAL SALES, 2007-2011 (USD MILLION)
  • FIG. 24 MERCK & CO, INC. ANNUAL REVENUE, 2007 - 2011 (USD MILLION)
  • FIG. 25 NOVARTIS AG. ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 26 SANOFI SA. ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 27 PFIZER INC. ANNUAL REVENUE, 2009-2011 (USD MILLION)
  • FIG. 28 TAKEDA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
  • FIG. 29 VALEANT PHARMACEUTICAL ANNUAL REVENUE, 2008-2011 (USD MILLION)
  • FIG. 30 WATSON PHARMACEUTICALS INC., 2007-2011 (USD MILLION)

LIST OF TABLES

  • TABLE 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET: SNAPSHOT
  • TABLE 2 GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2010 - 2018
  • TABLE 3 IMPACT ANALYSIS OF DRIVERS
  • TABLE 4 IMPACT ANALYSIS OF RESTRAINTS
  • TABLE 5 PIPELINE DRUGS FOR LIVER DISEASES THERAPEUTICS (PHASE III)
  • TABLE 6 RECENT AGREEMENT AND COLLABORATION OF KEY PLAYERS
Back to Top